GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: The Lancet Rheumatology, Elsevier BV, Vol. 4, No. 5 ( 2022-05), p. e329-e337
    Type of Medium: Online Resource
    ISSN: 2665-9913
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Immunology, Immunotherapy, Springer Science and Business Media LLC, Vol. 62, No. 7 ( 2013-7), p. 1211-1222
    Type of Medium: Online Resource
    ISSN: 0340-7004 , 1432-0851
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2013
    detail.hit.zdb_id: 1458489-X
    detail.hit.zdb_id: 195342-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: eJHaem, Wiley, Vol. 3, No. 3 ( 2022-08), p. 739-747
    Abstract: Burkitt lymphoma (BL) represents the most aggressive B‐cell‐lymphoma. Beside the hallmark of IG‐MYC ‐translocation, surface B‐cell receptor (BCR) is expressed, and mutations in the BCR pathway are frequent. Coincidental infections in endemic BL, and specific extra‐nodal sites suggest antigenic triggers. To explore this hypothesis, BCRs of BL cell lines and cases were screened for reactivities against a panel of bacterial lysates, lysates of Plasmodium falciparum , a custom‐made virome array and against self‐antigens, including post‐translationally modified antigens. An atypically modified, SUMOylated isoform of Bystin, that is, SUMO1‐BYSL was identified as the antigen of the BCR of cell line CA46. SUMO1‐BYSL was exclusively expressed in CA46 cells with K139 as site of the SUMOylation. Secondly, an atypically acetylated isoform of HSP40 was identified as the antigen of the BCR of cell line BL41. K104 and K179 were the sites of immunogenic acetylation, and the acetylated HSP40 isoform was solely present in BL41 cells. Functionally, addition of SUMO1‐BYSL and acetylated HSP40 induced BCR pathway activation in CA46 and BL41 cells, respectively. Accordingly, SUMO1‐BYSL‐ETA’ immunotoxin, produced by a two‐step intein‐based conjugation, led to the specific killing of CA46 cells. Autoantibodies directed against SUMO1‐BYSL were found in 3 of 14 (21.4%), and autoantibodies against acetylated HSP40 in 1/14(7.1%) patients with sporadic Burkitt‐lymphoma. No reactivities against antigens of the infectious agent spectrum could be observed. These results indicate a pathogenic role of autoreactivity evoked by immunogenic post‐translational modifications in a subgroup of sporadic BL including two EBV‐negative BL cell lines.
    Type of Medium: Online Resource
    ISSN: 2688-6146 , 2688-6146
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 3021452-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2013
    In:  Arthritis Research & Therapy Vol. 15, No. 6 ( 2013), p. R211-
    In: Arthritis Research & Therapy, Springer Science and Business Media LLC, Vol. 15, No. 6 ( 2013), p. R211-
    Type of Medium: Online Resource
    ISSN: 1478-6354
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2013
    detail.hit.zdb_id: 2041668-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Walter de Gruyter GmbH ; 1990
    In:  Biological Chemistry Hoppe-Seyler Vol. 371, No. 1 ( 1990-01), p. 215-222
    In: Biological Chemistry Hoppe-Seyler, Walter de Gruyter GmbH, Vol. 371, No. 1 ( 1990-01), p. 215-222
    Type of Medium: Online Resource
    ISSN: 0177-3593
    Language: English
    Publisher: Walter de Gruyter GmbH
    Publication Date: 1990
    detail.hit.zdb_id: 1466062-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    American Society of Hematology ; 2016
    In:  Blood Vol. 128, No. 22 ( 2016-12-02), p. 2055-2055
    In: Blood, American Society of Hematology, Vol. 128, No. 22 ( 2016-12-02), p. 2055-2055
    Abstract: Background: Lysolipids have been claimed to be involved in the origin of sporadic monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) and of Gaucher's associated MGUS/MM because lyso-glucosylceramide (LGL1) and lysophosphatidylcholine (LPC) were purported to be the target of the clonal immunoglobulin in 31% of patients with sporadic and 85% with Gaucher's associated MGUS/MM(Nair et al. N Engl J Med 2016;374:555-61). The low titers (1:250) of the reported anti-lysolipid reactivity raised doubts as to whether these reactivities were indeed mediated by the clonal immunoglobulin (paraprotein). Patients and Methods: We analyzed the sera from 96 patients with MGUS/MM for the presence of anti-lysolipid reactivity by means of immunofixation, ELISA, serum protein electrophoresis (SPSP) before and after absorption with sphingosine beads to remove antibodies against lysolipids and paraprotein-specific antigens (paratarg-7 and sumoylated HSP90), respectively, and Western blots. Moreover, the BCR from MGUS/MM with a paraprotein-mediated reactivity against paratarg-7 and HSP90 were cloned and expressed as Fab fragments and used to determine antigen specificity by direct antigen binding and antigen-competition assays. Results: The presence of antibody reactivity against LGL1 and LPC was demonstrated in 28/96 (29%) MGUS/MM patients, confirming the rate observed in Nair's study (31%). Seven of these 28 sera also contained reactivity against paratarg-7 and 2 against HSP90 (always at titers 〉 1x106). In none of the 28 lysolipd-reactive cases was the anti-lysolipd reactivity mediated by the clonal immunoglobulin as demonstrated by low antibody titers ( 〈 1:500), immunoglobulin subclasses different from the clonal immunoglobulin (as shown by immunofixation), inability of lysolipids to compete with specific antigens for binding with the clonal immunoglobulin or the recombinant B-cell receptor and demonstration by immunoglobulin affinity chromatography, that separated LGL1 reactivity from the monoclonal immunoglobulin. Absorption with sphingosine-beads completely removed the anti-lipd reactivity from the respective sera and the LGL1 immunoreactive bands after SPEP, but did not remove the monoclonal peak from the serum electrophoresis, while this was always the case with paratarg-7 (see figure) and HSP90 when they were the antigenic targets of the paraproteins. Anti-lysolipid reactivities were rare in 140 healthy controls (6%), but more frequent in 140 patients with autoimmune diseases (19%; p=0.002). Conclusions: Our data disprove a role of lysolipids in the origin of sporadic MGUS/MM. While we had no access to sera from patients with Gaucher'sassociated MGUS/MM, the report that lysolipds are the targets of the paraproteins in 85% of these cases and hence play a role in the pathogenesis of these diseases must also be met with caution. To prove that an observed antibody reactivity is mediated by the clonal immune globulin all of the following prerequisites must be met: 1st, the clonal immunoglobulin and the antibody mediating the reactivity against the antigen have the identical light and heavy chains; 2nd, the reaction has a serum titer 〉 1x106; 3rd, absorption with the antigen removes the monoclonal peak in the serum electrophoresis; 4th, a specific reactivity of the expressed (clonal) B-cell receptor with the antigen is demonstrated; and 5th, convincing data is provided by competition assays that the paraprotein and the B-cell receptor recognize the same antigen and epitope of the antigen under investigation. Not a single one of these prerequisites has been met in the study of Nair et al. A role of lysolipids in the pathogenesis of any form of MGUS/MM cannot be assumed until the complete set of the 5 prerequisites is demonstrated for these autoantigens. A request for exchange of sera has been forwarded to Nair et al., and if granted, results will be reported. Supported by Wilhelm-Sander-Stiftung. Figure Figure. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2016
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 4085-4085
    Abstract: Abstract 4085 Background: Hyperphosphorylated paratarg-7 (pP-7) is the target of paraproteins in 15% of patients with MGUS/MM (Preuss et al. Int J Cancer 2009; 125:656-61). Carriers of pP-7 have an 8-times increased risk to develop IgA/IgG-MGUS and multiple myeloma (Grass et al., Lancet Oncology 2009; 10:950-956) and a 6.5 times increased risk to develop IgM-MGUS and Waldenström′s macroglobulinemia (Grass et al., Blood 2009;114:1513s). Analysis of affected families showed that pP-7 is inherited in a dominant fashion. Thus, pP-7 is the first molecularly defined autosomal-dominant risk factor for any hematological neoplasm. Objective: Since paratarg-7, a frequent target of paraproteins in patients with MGUS/MM is hyperphosphorylated and inherited in a dominant fashion we extended our studies to investigate the prevalence of further antigenic targets and their phosphorylation state. Methods: Sera of MGUS/MM patients and relatives of affected families were tested for antibody reactivity against antigens represented in a fetal brain derived protein macroarray using a modified SEREX approach (Preuss et al. International J. Cancer 2009;125, 656–661). Lysates of peripheral blood from patients, family-members and controls were tested by gel electrophoresis and isoelectric focusing before and after phosphatase treatment. Results: Analysis of 3 families with multiple members affected by MGUS and MM revealed that the antigenic targets of paraproteins from affected members of a given family are identical: 2 families shared paratarg-7 and 1 family shared paratarg-8 as the family-typic paraprotein antigen. Paratarg-8 is encoded by the ATG13 gene, a member of the „autophagy regulatory complex“ family of genes. Paratarg-8 showed no mutations or polymorphisms in patients compared to controls. However, IEF before and after phosphatase treatment showed that paratarg-8 is hyperphosphorylated (pP-8) in the affected family members compared to healthy controls and that pP-8 carrier state is also inherited in a dominant fashion. This finding prompted us to check previously identified paraprotein targets for hyperphosphorylation, which, in addition to paratarg-7 and paratarg-8 was possible for paratarg 2, 5, 6, 9, 10, 11. In all 8/8 cases, IEF before and after phosphatase treatment revealed that the patients were carriers of a hyperphosphorylated version of their paraprotein target compared to healthy controls. Conclusions: The paraproteins of members affected by familial MGUS/MM are directed against family-specific antigenic targets, suggesting that the genetic background shared by these patients contains a chronic auto-immune response. Paratarg-7 and paratarg-8 are the first family-typic antigens that have been molecularly defined to date. The fact that all antigenic targets of paraproteins molecularly defined to date are hyperphosphorylated in patients compared to healthy controls implies a significant role of the hyperphosphorylation state in these neoplasms. Analysis of the T-cell response against normo- and hyperphosphorylated paraprotein targets in affected and non-affected family members is underway as are genome-wide association to determine the SNP or mutation which is associated with the hyperphosphorylation of paraprotein targets. Disclosures: Lynch: State of Nebraska LB595 support: Research Funding; Charles F. and Mary C. Heider Chair at Creighton University.: Research Funding.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2010
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Blood, American Society of Hematology, Vol. 121, No. 23 ( 2013-06-06), p. 4708-4717
    Abstract: Autoantigens bind to and induce proliferation of CLL cells, supporting chronic antigenic stimulation as an important pathomechanism in CLL.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Blood, American Society of Hematology, Vol. 118, No. 12 ( 2011-09-22), p. 3340-3346
    Abstract: Paratarg-7, a frequent autoantigenic target, and all other autoantigenic targets of human paraproteins molecularly defined to date are hyperphosphorylated in the respective patients compared with healthy controls, suggesting that hyperphosphorylation of autoantigenic paraprotein targets is a general mechanism underlying the pathogenesis of these paraproteins. We now show that hyperphosphorylation of paratarg-7 occurs because of an additional phosphorylation of Ser17, which is located within the paraprotein-binding epitope. Coimmunoprecipitation identified phosphokinase C ζ (PKCζ) as the kinase responsible for the phosphorylation of most, and phosphatase 2A (PP2A) as the phosphatase responsible for the dephosphorylation of all hyperphosphorylated autoantigenic targets of paraproteins. Single-nucleotide polymorphisms (SNPs) or mutations of PKCζ and PP2A were excluded. However, PP2A was inactivated by phosphorylation of its catalytic subunit at Y307. Stimulation of T cells from healthy carriers of wild-type paratarg-7 induced a partial and transient hyperphosphorylation between days 4 and 18, which was maintained by incubation with inhibitors of PP2A, again indicating that an inactivation of PP2A is responsible for the hyperphosphorylation of autoantigenic paraprotein targets. We conclude that the genetic defect underlying the dominantly inherited hyperphosphorylation of autoantigenic paraprotein targets is not in the PP2A itself, but in genes or proteins controlling PP2A activity by phosphorylation of its catalytic subunit.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2011
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 118, No. 21 ( 2011-11-18), p. 472-472
    Abstract: Abstract 472 Hyperphosphorylated paratarg-7 (pP-7) is the target of paraproteins in 15% of Caucasian, 4.5% of Asian and 28% of Afro-American patients with MGUS/MM. Carriers of pP-7 have an 8 to 13 times increased risk to develop IgA/IgG-MGUS and multiple myeloma (Grass et al., Lancet Oncology 2009; 10:950–956) and a 6.5 times increased risk to develop IgM-MGUS and Waldenstrom`s macroglobulinemia (Grass et al., Blood. 2011 Mar 10;117(10):2918–23.). Analysis of affected families showed that pP-7 is inherited in a dominant fashion, explaining cases of familial MGUS/MM/WM. Since paratarg-7 is hyperphosphorylated and inherited in a dominant fashion, we extended our studies to investigate the prevalence of further antigenic targets of paraproteins and their phosphorylation state. All (8/8) autoantigenic paraprotein target (paratargs no. 2, 5, 6, 7, 8, 9, 10, and 11) moleculary defined to date were shown to be hyperphosphorylated in the respective patients compared to normal controls, and the hyperphosphorylation state of the respective paraproteins targets was shown to be inherited in a dominant fashion for all autoantigenic paraprotein targets for which enough family members were available for such an analysis. The consistent finding of hyperphosphorylation of autoantigenic paraprotein targets suggests a common underlying mechanism associated with the pathogenesis of MGUS/MM, and implies a significant role of the hyperphosphorylation state in the pathogenesis of these neoplasms. Co-immunoprecipitation identified PKCzeta as the kinase responsible for the phosphorylation of most and PP2A as the phosphatase responsible for the dephosphorylation of all hyperphosphorylated autoantigenic targets of paraproteins. SNPs or mutations of PKCzeta and PP2A as the reason for the abnormal phosphorylation of the paraproteins targets were excluded. However, PP2A was shown to be inactivated by phosphorylation of its catalytic subunit at Y307. To determine the SNP or mutation which is associated with the inactivation of PP2A we carried out a genome-wide linkage analysis. We found strong evidence for a parametric linkage (full penetrant autosomal dominant model; disease marker allele frequency=0.02) with a LOD score of 5.9 on chromosome 4q35. For pP-7 hyperphosphorylation we demonstrated that the hyperphosphrylation is due to an single additional phosphorylation at serine 17, which is located in the paraprotein-binding epitope of pP-7. Analysis of the T-cell response against normo- and hyperphosphorylated paratarg-7 derived peptides in affected and non-affected family members demonstrated that pP-7, but not wild-type p-7 induces a strong and specific CD4+ T-cell response in the patients with pP-7, which was shown to be HLA-DQ and HLA-DR restricted. This suggests that pP-7 confers a chronic antigenic stimulation which is mediated by CD4+ T-cells and that these pP-7 specific CD4+ T-cells stimulate a B-cell clone with the same specificity, eventually resulting in the clonal evolution of this B-cell clone. In summary, our results support the hypothesis of a role of chronic autoantigenic stimulation in the pathogenesis of MGUS/MM/WM. Indviduals carrying pP-7 are at particular risk, if their MHC-II haplotype allows the recognition of pP-7 derived antigenic peptides by their CD4+ T cells. We suggest that the different prevalence of pP-7 carriers and defined MHC-II haplotypes explain the different incidence rates of MGUS/MM/WM in different ethnic groups. Disclosures: Preuss: Ludwig Institute for Cancer Research: Patents & Royalties. Pfreundschuh:Ludwig Institute for Cancer Research: Patents & Royalties.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2011
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...